ClinicalTrials.gg
Enrolling by invitationNCT07804342Updated Sep 4, 2026

Ankle Robotics for Error Augmentation After Stroke

An interventional study of AMBLE in Chronic Stroke, sponsored by University of Maryland, Baltimore. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jun 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 88 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Stroke by University of Maryland, Baltimore — 7 open to participants now, 7 under way, none of them phase 3. Stroke · University of Maryland, Baltimore.

Planned enrollment
9th of 11
10 · median 32
Started
2025
with 1 other
No phase
9 of 13
4 open now
Registered
12th of 13
by date

Among the 13 studies in Stroke by University of Maryland, Baltimore, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, and was the 12th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

7 of the 13 studies in Stroke by University of Maryland, Baltimore are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 88 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Stroke by University of Maryland, Baltimore, or all of them as a file.
02

Study summary

The goal of this pilot clinical trial is to test whether training with a portable ankle robot improves ankle push-off and walking speed in adults with chronic stroke who have ankle weakness. The study will also evaluate whether the device is safe and practical to use during walking rehabilitation.

The main questions it aims to answer are:

Does training with the portable ankle robot improve paretic ankle propulsion during walking? Does training with the portable ankle robot improve walking speed at self-selected and fast walking speeds?

Participants will:

Complete 30 training sessions of treadmill and overground walking while wearing the portable ankle robot, 3 to 4 times per week over 8 to 9 weeks Complete walking and movement assessments before training, after 15 sessions, and after 30 sessions Walk at self-selected and fast speeds while researchers measure ankle propulsion, gait symmetry, and walking speed

Read the detailed description

This is a single-arm pilot study evaluating robotic error augmentation of paretic ankle propulsion during gait training in adults with chronic stroke. Ten participants with chronic (>6 months) stroke and residual ankle weakness will complete 30 training sessions using the AMBLE portable ankle exoskeleton. Assessments are conducted at baseline, after 15 sessions, and after 30 sessions. The hypothesis is that 30 sessions of robot-assisted treadmill gait training enhances paretic ankle plantarflexion propulsive torque and gait symmetry.

Approximately half of stroke survivors are left with chronic mobility disability, typically involving ankle weakness that impairs walking and increases fall risk. Current care relies on ankle-foot orthoses, functional electrical stimulation, canes, and walkers, none of which address the underlying deficit in ankle motor control. Weakness of the paretic plantarflexors limits push-off during late stance, reducing forward propulsion and contributing to reduced walking speed and gait asymmetry.

The investigators previously developed the AMBLE, a lightweight portable ankle exoskeleton that uses impedance-based control with real-time gait event detection to deliver torque synchronized to specific phases of the gait cycle. Prior work by this group using laboratory-based and portable ankle robotics targeted dorsiflexion, demonstrating reduced foot drop and improved overground walking in both early and chronic stroke, and the present study extends an ongoing investigation of the device (NCT04594837). Paretic plantarflexion propulsion has not previously been targeted with the AMBLE. Recent engineering modifications enable graded resistance during the push-off phase of gait, permitting investigation of whether error augmentation applied to paretic ankle propulsion can enhance forward propulsion during walking.

Training sessions consists of two 10-minute bouts of treadmill walking at progressively increasing speed and one 10-minute bout of overground walking as able, with the robot donned on the paretic leg. Plantarflexion resistance is delivered through the ankle robot and calibrated individually, increased as tolerated up to the level just below the point at which hip circumduction or instability emerges. Resistance is applied after attainment of steady-state walking speed and intermittently removed at predetermined intervals to sample voluntary paretic ankle power. Treadmill speed is then progressed toward a target of 70-85% heart rate reserve and RPE 15-18, recorded every 3-5 minutes. Seated rest of 2-3 minutes is provided between bouts.

Visual feedback of ankle propulsion power is delivered through a tablet-based application on a faded schedule: continuously during weeks 1-2, for 1 minute every 5 minutes during weeks 3-4, for 1 minute at the end of each 10-minute bout during weeks 5-6, and as terminal summary feedback during seated rest in weeks 7-9.

Assessments include the 10-meter walk test at self-selected and fastest comfortable speeds; overground gait biomechanics using an instrumented walkway for spatiotemporal parameters and gait symmetry and two force plates for propulsive torque during push-off; and paretic and non-paretic ankle power normalized to body mass with kinetic symmetry, collected during unassisted walking with the device in evaluation mode. The Fugl-Meyer Assessment for the Lower Extremity is administered at baseline. Baseline and post-training measures will be compared using paired t-tests or nonparametric equivalents. Findings will provide preliminary effect estimates to inform the design of a larger trial.

03

Conditions studied

  • Chronic Stroke

Browse trials for

Keywords

  • error augmentation
  • robotics
  • device
  • walking
04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic stroke, more than 6 months post-stroke
  • Clinical evidence of hemiparetic gait
  • Ankle dorsiflexion and plantarflexion strength on the affected side graded 1/5 (trace contraction) to 4/5 (reduced strength) on manual muscle testing
  • Able to independently complete the 10-Meter Walk Test at a walking speed less than 1.0 m/s, with or without an assistive device

Exclusion criteria

Exclusion Criteria:

  • Self-reported unstable angina, myocardial infarction within the past 3 months, congestive heart failure ( Class II), or hemodynamically significant valvular disease
  • Self-reported hypertension that is a to routine physical therapy (greater than 160/100 mmHg on two assessments)
  • Self-reported hospitalization within the past 3 months for severe medical illness
  • Self-reported symptomatic peripheral arterial occlusive disease
  • Self-reported orthopedic conditions or chronic pain that significantly alter gait function
  • Self-reported pulmonary or renal failure
  • Self-reported active cancer
  • Self-reported history of a non-stroke neuromuscular disorder restricting gait
  • Aphasia or cognitive functioning that confounds participation, defined as unable to follow two-step commands or by judgment of the evaluating therapist
  • Self-reported history of cerebellar stroke or observable cerebellar signs
  • Self-reported botulinum toxin prescribed for the lower extremities within the previous 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    AMBLE Robotic Gait Training

    Participants with chronic stroke will receive a 30-session gait training program using the AMBLE portable robotic ankle exoskeleton. Training will include treadmill and overground walking with individualized robotic resistance to improve ankle plantarflexion during push-off. Robotic assistance will be adjusted throughout the intervention based on participant performance and tolerance to promote active motor recovery and improve walking function.

    Device: AMBLE

Interventions

  • DeviceAMBLE

    The AMBLE is a portable robotic ankle exoskeleton designed to provide individualized assistance and/or resistance during gait training. The device uses adaptive impedance-based control and real-time gait detection to provide dorsiflexion assistance during swing and plantarflexion assistance or resistance during push-off based on participant performance. It is used during treadmill and overground walking to promote recovery of ankle motor control and walking function.

06

What researchers measure

Primary outcomes

  1. Peak ankle plantarflexion propulsive torque during walking

    Peak ankle plantarflexion propulsive torque will be measured using force plates during overground walking to quantify propulsion generated by the paretic limb during the push-off phase of gait.

    Time frame: Baseline (prior to intervention), 5 weeks after intervention initiation (following approximately 15 sessions), and 10 weeks after intervention initiation (following approximately 30 sessions)

Secondary outcomes

  1. Self-selected walking speed

    Self-selected walking speed will be assessed using the 10-Meter Walk Test and reported in meters per second.

    Time frame: Baseline (prior to intervention), 5 weeks after intervention initiation (following approximately 15 training sessions), and 10 weeks after intervention initiation (following approximately 30 training sessions)

  2. Fast walking speed

    Maximum comfortable walking speed will be assessed using the 10-Meter Walk Test and reported in meters per second.

    Time frame: Baseline (prior to intervention), 5 weeks after intervention initiation (following approximately 15 training sessions), and 10 weeks after intervention initiation (following approximately 30 training sessions)

  3. Step Length Symmetry Ratio During Overground Walking Measured by Instrumented Walkway

    Step length symmetry ratio computed as paretic step length divided by non-paretic step length from spatiotemporal data collected during overground walking on a GAITRite instrumented walkway. A ratio of 1.0 indicates perfect symmetry between limbs; values below 1.0 indicate shorter paretic steps and values above 1.0 indicate longer paretic steps. Values are averaged across \[N\] walkway passes at self-selected walking speed at each assessment timepoint. Unit of Measure: ratio

    Time frame: Baseline (prior to intervention), 5 weeks after intervention initiation (following approximately 15 training sessions), and 10 weeks after intervention initiation (following approximately 30 training sessions)

07

Study locations

2 sites
  • Allied Health Research Building
    Baltimore, Maryland 21042, United States
  • Allied Health Research Building
    Baltimore, Maryland 21201, United States
08

References and documents

Publications

  • Forrester LW, Roy A, Krebs HI, Macko RF. Ankle training with a robotic device improves hemiparetic gait after a stroke. Neurorehabil Neural Repair. 2011 May;25(4):369-77. doi: 10.1177/1545968310388291. Epub 2010 Nov 29. PubMed 21115945 ↗
  • Forrester LW, Roy A, Krywonis A, Kehs G, Krebs HI, Macko RF. Modular ankle robotics training in early subacute stroke: a randomized controlled pilot study. Neurorehabil Neural Repair. 2014 Sep;28(7):678-87. doi: 10.1177/1545968314521004. Epub 2014 Feb 10. PubMed 24515923 ↗
  • Macko RF, Ivey FM, Forrester LW, Hanley D, Sorkin JD, Katzel LI, Silver KH, Goldberg AP. Treadmill exercise rehabilitation improves ambulatory function and cardiovascular fitness in patients with chronic stroke: a randomized, controlled trial. Stroke. 2005 Oct;36(10):2206-11. doi: 10.1161/01.STR.0000181076.91805.89. Epub 2005 Sep 8. PubMed 16151035 ↗
  • Macko RF, Ivey FM, Forrester LW. Task-oriented aerobic exercise in chronic hemiparetic stroke: training protocols and treatment effects. Top Stroke Rehabil. 2005 Winter;12(1):45-57. doi: 10.1310/PJQN-KAN9-TTVY-HYQH. PubMed 15736000 ↗
  • Westlake KP, Dudek K, Roy A, Henderson CE, Hornby TG. The Concept of Shaping Applied to Locomotor Interventions: Clinical and Robotic Strategies to Facilitate and Progress Variable Stepping Training at Higher Intensities. Neurorehabil Neural Repair. 2026 Jun 15:15459683261454948. doi: 10.1177/15459683261454948. Online ahead of print. PubMed 42290198 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 25 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Sep 4, 2026
StartActual
Jun 16, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07804342
Collaborators
NextStep Robotics Inc.
Responsible party
Kelly Westlake (Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Sep 4, 2026
Start date
Jun 16, 2025
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Kelly Westlake, PhD, PT
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion